Sepio Capital LP Decreases Position in Cerus Corporation $CERS

Sepio Capital LP reduced its stake in Cerus Corporation (NASDAQ:CERS - Free Report) by 52.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 303,500 shares of the biotechnology company's stock after selling 340,000 shares during the period. Sepio Capital LP owned approximately 0.16% of Cerus worth $422,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC raised its holdings in Cerus by 218.5% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 50,972 shares of the biotechnology company's stock valued at $71,000 after buying an additional 34,968 shares during the period. Pallas Capital Advisors LLC acquired a new position in Cerus in the 1st quarter valued at about $37,000. R Squared Ltd grew its position in Cerus by 106.7% in the 1st quarter. R Squared Ltd now owns 38,655 shares of the biotechnology company's stock valued at $54,000 after acquiring an additional 19,955 shares in the last quarter. Stifel Financial Corp grew its position in Cerus by 6.7% in the 4th quarter. Stifel Financial Corp now owns 282,350 shares of the biotechnology company's stock valued at $435,000 after acquiring an additional 17,678 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Cerus by 6.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,774,137 shares of the biotechnology company's stock valued at $2,466,000 after acquiring an additional 107,771 shares in the last quarter. 78.37% of the stock is currently owned by hedge funds and other institutional investors.

Cerus Stock Down 1.6%

Shares of Cerus stock traded down $0.02 on Friday, reaching $1.23. 685,808 shares of the company were exchanged, compared to its average volume of 1,113,494. Cerus Corporation has a 1-year low of $1.12 and a 1-year high of $2.24. The company has a market cap of $235.79 million, a P/E ratio of -12.30 and a beta of 1.63. The company has a debt-to-equity ratio of 1.01, a current ratio of 2.00 and a quick ratio of 1.35. The stock's 50 day moving average price is $1.32 and its 200-day moving average price is $1.36.

Cerus (NASDAQ:CERS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biotechnology company reported ($0.03) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.01). Cerus had a negative return on equity of 33.77% and a negative net margin of 9.81%.The company had revenue of $60.10 million for the quarter, compared to analyst estimates of $51.80 million. Cerus has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Cerus Corporation will post -0.08 EPS for the current year.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.